跳至主要内容
临床试验/NCT03212781
NCT03212781已完成3 期

Total Dose Infusion of Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women: a Randomized Controlled Trial

Assiut University1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2016年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
66
试验地点
1
主要终点
The change in Hemoglobin concentration from baseline to 8 weeks therapy

研究概览

简要总结

Iron deficiency is the most prevalent nutritional deficiency and the most common cause of anemia .It is characterized by a defect in hemoglobin synthesis, resulting in red blood cells that are abnormally small (microcytic) and contain a decreased amount of hemoglobin (hypochromic).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Hemoglobin < 10 g/dL
  • Gestational age between 14-28 weeks.
  • Willingness to participate and signing the informed consent form.

排除标准

  • Iron overload or disturbances in utilization of iron
  • Decompensated liver cirrhosis and active hepatitis
  • Active acute or chronic infections
  • History of multiple allergies
  • Known hypersensitivity to parenteral iron or any recipients in the investigation drug products
  • Erythropoietin treatment within 8 weeks prior to the screening visit
  • Other iron treatment or blood transfusion within 4 weeks prior to the screening visit
  • Planned elective surgery during the study.

研究组 & 干预措施

intravenous iron

Experimental

patients will receive intravenous iron as total dose infusion

干预措施: Iron dextran (Drug)

oral iron

Active Comparator

patients will receive oral iron

干预措施: Ferrous Fumarate (Drug)

结局指标

主要结局

The change in Hemoglobin concentration from baseline to 8 weeks therapy

时间窗: 8 weeks

measure hemoglobin level before and after treatment

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Mohamed Abbas

Principal investigator

Assiut University

研究点 (1)

Loading locations...

相似试验